Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose cancer had progressed after multiple prior lines of therapy The majority of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback